746 results on '"Stenzl, A."'
Search Results
2. PD36-01 NECTIN-4 PROTEIN EXPRESSION IN MUSCLE INVASIVE BLADDER CANCER - SELECTIVE PREDICTOR OR CONSISTENTLY EXPRESSED IN TUMOR TISSUE?
3. PD36-01 NECTIN-4 PROTEIN EXPRESSION IN MUSCLE INVASIVE BLADDER CANCER - SELECTIVE PREDICTOR OR CONSISTENTLY EXPRESSED IN TUMOR TISSUE?
4. MP14-19 ALTERATIONS OF INSULIN SIGNALING AND TUMOR BIOLOGY IN UROTHELIAL CARCINOMA OF DIABETIC AND NON-DIABETIC PATIENTS
5. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
6. Editorial Comment
7. MP27-14 OVERALL SURVIVAL IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE OR PLACEBO PLUS ANDROGEN DEPRIVATION THERAPY WHO HAD PRIOR LOCAL THERAPY: POST HOC ANALYSIS OF THE PHASE 3 ARCHES TRIAL
8. MP06-06 ESTABLISHMENT AND EVALUATION OF A SIMPLIFIED APPROACH TO PATIENT DERIVED BLADDER CANCER ORGANOIDS USING URINE
9. PD53-02 CYTOTOXICITY CAUSED BY CISPLATIN, VENETOCLAX, AND S63845 TO UROTHELIAL CARCINOMA CELLS EXPANDED IN 3D ORGANOIDS DIFFERS CLEARLY FROM CYTOTOXICITY TO AUTOLOGOUS 2D ADHERENT CELLS
10. MP06-06 ESTABLISHMENT AND EVALUATION OF A SIMPLIFIED APPROACH TO PATIENT DERIVED BLADDER CANCER ORGANOIDS USING URINE
11. MP27-14 OVERALL SURVIVAL IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE OR PLACEBO PLUS ANDROGEN DEPRIVATION THERAPY WHO HAD PRIOR LOCAL THERAPY: POST HOC ANALYSIS OF THE PHASE 3 ARCHES TRIAL
12. PD53-02 CYTOTOXICITY CAUSED BY CISPLATIN, VENETOCLAX, AND S63845 TO UROTHELIAL CARCINOMA CELLS EXPANDED IN 3D ORGANOIDS DIFFERS CLEARLY FROM CYTOTOXICITY TO AUTOLOGOUS 2D ADHERENT CELLS
13. PD34-07 ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES
14. PD34-10 IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
15. PD34-07 ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES
16. PD34-10 IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
17. Reply by Authors
18. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
19. Editorial Comment
20. PD10-10 IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY
21. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA
22. Clinicopathological Features and Prognostic Value of Incidental Prostatic Adenocarcinoma in Radical Cystoprostatectomy Specimens: A Systematic Review and Meta-Analysis of 13,140 Patients
23. LBA-10 ARCHES – EFFICACY OF ANDROGEN DEPRIVATION THERAPY WITH ENZALUTAMIDE OR PLACEBO IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: PROSTATE-SPECIFIC ANTIGEN RESULTS
24. PD47-06 THE PROGNOSTIC SIGNIFICANCE OF THE ANDROGEN RECEPTOR GENE AND SINGLE NUCLEOTIDE POLYMORPHISMS IN ANDROGEN-REGULATED GENES IN PATIENTS WITH CONCOMITANT BLADDER AND PROSTATE CANCER
25. MP13-13 ROBOTIC TRANSRECTAL COMPUTED TOMOGRAPHIC ULTRASOUND WITH ARTIFICIAL NEURAL NETWORK ANALYSIS – FIRST VALIDATION AND COMPARISON WITH MRI-GUIDED BIOPSIES AND RADICAL PROSTATECTOMY
26. MP57-18 PROGNOSTIC IMPACT OF TUMOR-ASSOCIATED ROUND CELL INFILTRATES AT RADICAL CYSTECTOMY FOR BLADDER CANCER
27. PD23-06 DETECTION RATE OF PROSTATE CANCER AT TARGET BIOPSY AFTER 3 DIFFERENT TECHNICAL APPROACHES
28. MP29-03 MTOR EXPRESSION IN PROSTATE CANCER AND IMPLICATIONS AS PROGNOSTIC ROLE WITH META-ANALYSIS OF THE LITERATURE
29. PD45-05 COMPARATIVE ANALYSIS OF PHYSICAL AND OPTICAL PROPERTIES OF SINGLE-USE VERSUS REUSABLE URETERORENOSCOPES FOR RETROGRADE INTRARENAL SURGERY (RIRS)
30. MP41-03 EXPRESSION OF SOMATOSTATIN RECEPTORS IN PATIENTS WITH ADVANCED BLADDER CANCER IS AN INDICATOR FOR FAVORABLE OUTCOME
31. MP78-17 LONG-TERM ONCOLOGICAL OUTCOMES AFTER TRIMODALITY THERAPY AND RADICAL CYSTECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
32. PD12-01 DOES CO-MEDICATION WITH NON-ANTICANCER DRUGS AFFECT OUTCOMES IN PATIENTS WITH SURGICALLY TREATED CLEAR CELL RENAL CELL CARCINOMA ? - EVALUATION OF SURVIVAL, CELL-CYCLE ACTIVITY, AND PROLIFERATION
33. PD47-06 THE PROGNOSTIC SIGNIFICANCE OF THE ANDROGEN RECEPTOR GENE AND SINGLE NUCLEOTIDE POLYMORPHISMS IN ANDROGEN-REGULATED GENES IN PATIENTS WITH CONCOMITANT BLADDER AND PROSTATE CANCER
34. LBA-10 ARCHES – EFFICACY OF ANDROGEN DEPRIVATION THERAPY WITH ENZALUTAMIDE OR PLACEBO IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: PROSTATE-SPECIFIC ANTIGEN RESULTS
35. MP57-18 PROGNOSTIC IMPACT OF TUMOR-ASSOCIATED ROUND CELL INFILTRATES AT RADICAL CYSTECTOMY FOR BLADDER CANCER
36. MP13-13 ROBOTIC TRANSRECTAL COMPUTED TOMOGRAPHIC ULTRASOUND WITH ARTIFICIAL NEURAL NETWORK ANALYSIS – FIRST VALIDATION AND COMPARISON WITH MRI-GUIDED BIOPSIES AND RADICAL PROSTATECTOMY
37. MP64-17 REDUCTION OF POSITIVE SURGICAL MARGINS DUE TO A SIMPLIFIED NEUROSAFE TECHNIQUE
38. MP87-06 EXPRESSION ANALYSIS OF TUMOR PROMOTING GENES IN CIRCULATING TUMOR CELLS OF PATIENTS WITH LOCALIZED AND METASTATIC PROSTATE CANCER
39. MP34-15 A EUROPEAN MULTI-CENTRE REPORT ON CURRENT NEOADJUVANT CHEMOTHERAPY ADMINISTRATION RATES IN ROBOT-ASSISTED RADICAL CYSTECTOMY PATIENTS AND THE IMPACT ON PATHOLOGICAL STAGING
40. MP99-09 PROSTATE CANCER GENOMICS – IDENTIFICATION OF PROGNOSTIC MARKERS FROM THE BONE MARROW
41. MP40-09 ESTABLISHMENT OF A NEW LARGE ANIMAL MODEL FOR STRESS URINARY INCONTINENCE USING GERMAN LANDRACE PIGS
42. MP36-01 COLLAGEN CELL CARRIER FOR URETHRAL RECONSTRUCTIVE SURGERY: FIRST RESULTS OF A LONG-TERM MINIPIG MODEL
43. MP88-01 THE PROGNOSTIC VALUE OF PRE-CYSTECTOMY SERUM G-GLUTAMYLTRANSFERASE LEVELS IN PATIENTS WITH INVASIVE BLADDER CANCER
44. Editorial Comment
45. PD45-05 COMPARATIVE ANALYSIS OF PHYSICAL AND OPTICAL PROPERTIES OF SINGLE-USE VERSUS REUSABLE URETERORENOSCOPES FOR RETROGRADE INTRARENAL SURGERY (RIRS)
46. PD23-06 DETECTION RATE OF PROSTATE CANCER AT TARGET BIOPSY AFTER 3 DIFFERENT TECHNICAL APPROACHES
47. PD12-01 DOES CO-MEDICATION WITH NON-ANTICANCER DRUGS AFFECT OUTCOMES IN PATIENTS WITH SURGICALLY TREATED CLEAR CELL RENAL CELL CARCINOMA ? - EVALUATION OF SURVIVAL, CELL-CYCLE ACTIVITY, AND PROLIFERATION
48. MP41-03 EXPRESSION OF SOMATOSTATIN RECEPTORS IN PATIENTS WITH ADVANCED BLADDER CANCER IS AN INDICATOR FOR FAVORABLE OUTCOME
49. MP29-03 MTOR EXPRESSION IN PROSTATE CANCER AND IMPLICATIONS AS PROGNOSTIC ROLE WITH META-ANALYSIS OF THE LITERATURE
50. MP78-17 LONG-TERM ONCOLOGICAL OUTCOMES AFTER TRIMODALITY THERAPY AND RADICAL CYSTECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.